The case arose from assertions of patent infringement in the US and UK made by Dr. Fleur Tehrani. The Federal Circuit ultimately held the challenged claims of the asserted patent to be invalid, clearing the way for Hamilton to proceed with pending FDA approval of its INTELLiVENT®-ASV® (
The Federal Circuit’s decision also aligns with a final decision in favor of Hamilton handed down by the the United Kingdom’s Intellectual Property Enterprise Court in 2022.
This decision brings both patent disputes in the US and UK to a successful end for Hamilton.
Hamilton Technologies LLC v. Fleur Tehrani, U.S. Court of Appeals For The Federal Circuit, 2022-1732